Antonio Bernardo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Antonio Bernardo has a total of 743 co-authors. Here are the top co-authors by number of shared publications:
- Raffaella Palumbo
Oncologia Medica, Fondazione S. Maugeri IRCCS, 27100 Pavia, Italy
13 shared publications - Erica Quaquarini
Medical Oncology Unit, ICS Maugeri-IRCCS SpA SB, 27100 Pavia, Italy
8 shared publications Federico Sottotetti
Medical Oncology, Istituti Clinici Scientifici Maugeri IRCCS, Via Salvatore Maugeri, 8-10, 27100, Pavia, Italy
8 shared publicationsCristina Teragni
7 shared publications- Mara Frascaroli
Translational Oncology Unit, IRCCS ICS Maugeri SpA SB, Pavia, Italy
5 shared publications - Saverio Cinieri
Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy
5 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00017
CSF3R/CD114: Um preditor relacionado à pior sobrevida nos gliomas
Introduction: Gliomas are the most frequent primary brain tumors, accounting for more than 80% of all primary neoplasms of the central nervous system. These tumors are classified into different histological subtypes, the main ones being astrocytoma, oligodendroglioma, and glioblastoma. Among them, glioblastoma stands out as the most common and aggressive subtype, associated with a poor prognosis, even in the face of multimodal therapeutic approaches that combine surgical resection, radiotherapy, and chemotherapy with temozolomide. Objective: To analyze the association of CD114 expression with survival in patients with glioma. Method: The articles were selected by searching the following databases: Virtual Health Library (VHL), Medline, PubMed, and SciELO. The descriptors used were "CSF3R, CD114, colony-stimulating factor of granulocytes, glioma, glioblastoma, brain tumor", performing advanced search by combining them with the Boolean operator AND. Result: A total of 95 articles were analyzed. Conclusion: There is an association between high expression of CSF3R/CD114 with worst prognosis of patients, reflected by the reduction in overall survival in different types of glial tumors.
- 29 May 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00017
Open AccessCSF3R/CD114: Um preditor relacionado à pior sobrevida nos gliomas
Introduction: Gliomas are the most frequent primary brain tumors, accounting for more than 80% of all primary neoplasms of the central nervous system. These tumors are classified into different histological subtypes, the main ones being astrocytoma, oligodendroglioma, and glioblastoma. Among them, glioblastoma stands out as the most common and aggressive subtype, associated with a poor prognosis, even in the face of multimodal therapeutic approaches that combine surgical resection, radiotherapy, and chemotherapy with temozolomide. Objective: To analyze the association of CD114 expression with survival in patients with glioma. Method: The articles were selected by searching the following databases: Virtual Health Library (VHL), Medline, PubMed, and SciELO. The descriptors used were "CSF3R, CD114, colony-stimulating factor of granulocytes, glioma, glioblastoma, brain tumor", performing advanced search by combining them with the Boolean operator AND. Result: A total of 95 articles were analyzed. Conclusion: There is an association between high expression of CSF3R/CD114 with worst prognosis of patients, reflected by the reduction in overall survival in different types of glial tumors.
- Open Access
- 29 May 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00017
CSF3R/CD114: A predictor related to worse survival in gliomas
Introduction: Gliomas are the most frequent primary brain tumors, accounting for more than 80% of all primary neoplasms of the central nervous system. These tumors are classified into different histological subtypes, the main ones being astrocytoma, oligodendroglioma, and glioblastoma. Among them, glioblastoma stands out as the most common and aggressive subtype, associated with a poor prognosis, even in the face of multimodal therapeutic approaches that combine surgical resection, radiotherapy, and chemotherapy with temozolomide. Objective: To analyze the association of CD114 expression with survival in patients with glioma. Method: The articles were selected by searching the following databases: Virtual Health Library (VHL), Medline, PubMed, and SciELO. The descriptors used were "CSF3R, CD114, colony-stimulating factor of granulocytes, glioma, glioblastoma, brain tumor", performing advanced search by combining them with the Boolean operator AND. Result: A total of 95 articles were analyzed. Conclusion: There is an association between high expression of CSF3R/CD114 with worst prognosis of patients, reflected by the reduction in overall survival in different types of glial tumors.
- 29 May 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00017
Open AccessCSF3R/CD114: A predictor related to worse survival in gliomas
Introduction: Gliomas are the most frequent primary brain tumors, accounting for more than 80% of all primary neoplasms of the central nervous system. These tumors are classified into different histological subtypes, the main ones being astrocytoma, oligodendroglioma, and glioblastoma. Among them, glioblastoma stands out as the most common and aggressive subtype, associated with a poor prognosis, even in the face of multimodal therapeutic approaches that combine surgical resection, radiotherapy, and chemotherapy with temozolomide. Objective: To analyze the association of CD114 expression with survival in patients with glioma. Method: The articles were selected by searching the following databases: Virtual Health Library (VHL), Medline, PubMed, and SciELO. The descriptors used were "CSF3R, CD114, colony-stimulating factor of granulocytes, glioma, glioblastoma, brain tumor", performing advanced search by combining them with the Boolean operator AND. Result: A total of 95 articles were analyzed. Conclusion: There is an association between high expression of CSF3R/CD114 with worst prognosis of patients, reflected by the reduction in overall survival in different types of glial tumors.
- Open Access
- 3 April 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00009
Icu and antimicrobial resistance: How to face an everincreasing challenge?
Introduction: Antimicrobial resistance in critical care units represents one of the main challenges of health care, associated with high morbidity and unfavorable prognostic impact. Objective: To analyze the epidemiological dynamics, microbiological profile, risk factors, and prognostic impact of antimicrobial resistance in intensive care units, considering different patient profiles. Method: This is an integrative literature review based on the analysis of 20 scientific articles that investigated healthcareassociated infections, pathogen prevalence, and bacterial resistance in different critical care settings. Results: There was a predominance of gram-negative bacilli, especially microorganisms associated with high clinical severity, especially in ventilator-associated lung infections and bloodstream infections. Patients in specialized units, such as burns, pediatric, neonatal, and liver units, showed specific vulnerabilities. In addition, inadequacies in the nursing team sizing were associated with increased risk of microorganism dissemination. Conclusion: The reduction of antimicrobial resistance in these contexts requires an integrated approach, including programs for the rational use of antimicrobials, incorporation of rapid diagnostic methods, strict adherence to preventive measures, and adequacy of the workload of health professionals.
- 3 April 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00009
Open AccessIcu and antimicrobial resistance: How to face an everincreasing challenge?
Introduction: Antimicrobial resistance in critical care units represents one of the main challenges of health care, associated with high morbidity and unfavorable prognostic impact. Objective: To analyze the epidemiological dynamics, microbiological profile, risk factors, and prognostic impact of antimicrobial resistance in intensive care units, considering different patient profiles. Method: This is an integrative literature review based on the analysis of 20 scientific articles that investigated healthcareassociated infections, pathogen prevalence, and bacterial resistance in different critical care settings. Results: There was a predominance of gram-negative bacilli, especially microorganisms associated with high clinical severity, especially in ventilator-associated lung infections and bloodstream infections. Patients in specialized units, such as burns, pediatric, neonatal, and liver units, showed specific vulnerabilities. In addition, inadequacies in the nursing team sizing were associated with increased risk of microorganism dissemination. Conclusion: The reduction of antimicrobial resistance in these contexts requires an integrated approach, including programs for the rational use of antimicrobials, incorporation of rapid diagnostic methods, strict adherence to preventive measures, and adequacy of the workload of health professionals.
- Open Access
- 3 April 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00009
Utis e resistência antimicrobiana: Como enfrentar um desafio cada vez maior?
Introdução: A resistência antimicrobiana em unidades de cuidados críticos representa um dos principais desafios da assistência à saúde, associando-se à elevada morbidade e impacto prognóstico desfavorável. Objetivo: Analisar a dinâmica epidemiológica, o perfil microbiológico, os fatores de risco e o impacto prognóstico da resistência antimicrobiana em unidades de terapia intensiva, considerando diferentes perfis de pacientes. Método: Trata-se de revisão integrativa da literatura baseada na análise de 20 artigos científicos que investigaram infecções relacionadas à assistência à saúde, prevalência de patógenos e resistência bacteriana em diferentes cenários de cuidados críticos. Resultados: Observou-se predominância de bacilos Gram-negativos, com destaque para microrganismos associados à elevada gravidade clínica, especialmente em infecções pulmonares associadas à ventilação e infecções da corrente sanguínea. Pacientes em unidades especializadas, como as de queimados, pediátricas, neonatais e hepáticas, apresentaram vulnerabilidades específicas. Além disso, inadequações no dimensionamento da equipe de enfermagem mostraram-se associadas ao aumento do risco de disseminação de microrganismos. Conclusão: A redução da resistência antimicrobiana nesses contextos requer abordagem integrada, incluindo programas de uso racional de antimicrobianos, incorporação de métodos diagnósticos rápidos, adesão rigorosa a medidas preventivas e adequação da carga de trabalho dos profissionais de saúde.
- 3 April 2026
- Published by Associacao Medica do Parana in BioSCIENCE
- Vol. 84 (pt.e.) , 00009
Open AccessUtis e resistência antimicrobiana: Como enfrentar um desafio cada vez maior?
Introdução: A resistência antimicrobiana em unidades de cuidados críticos representa um dos principais desafios da assistência à saúde, associando-se à elevada morbidade e impacto prognóstico desfavorável. Objetivo: Analisar a dinâmica epidemiológica, o perfil microbiológico, os fatores de risco e o impacto prognóstico da resistência antimicrobiana em unidades de terapia intensiva, considerando diferentes perfis de pacientes. Método: Trata-se de revisão integrativa da literatura baseada na análise de 20 artigos científicos que investigaram infecções relacionadas à assistência à saúde, prevalência de patógenos e resistência bacteriana em diferentes cenários de cuidados críticos. Resultados: Observou-se predominância de bacilos Gram-negativos, com destaque para microrganismos associados à elevada gravidade clínica, especialmente em infecções pulmonares associadas à ventilação e infecções da corrente sanguínea. Pacientes em unidades especializadas, como as de queimados, pediátricas, neonatais e hepáticas, apresentaram vulnerabilidades específicas. Além disso, inadequações no dimensionamento da equipe de enfermagem mostraram-se associadas ao aumento do risco de disseminação de microrganismos. Conclusão: A redução da resistência antimicrobiana nesses contextos requer abordagem integrada, incluindo programas de uso racional de antimicrobianos, incorporação de métodos diagnósticos rápidos, adesão rigorosa a medidas preventivas e adequação da carga de trabalho dos profissionais de saúde.
- Open Access
- 24 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 679
Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
Introduction: Immune checkpoint inhibitors (ICIs) have become the standard of treatment for patients with non-small cell lung cancer (NSCLC). However, there are still many uncertainties regarding the selection of the patient who could benefit more from this treatment. This study aims to evaluate the prognostic and predictive role of clinical and biological variables in unselected patients with advanced NSCLC candidates to receive ICIs. Methods: This is an observational and prospective study. The primary objective is the evaluation of the relationship between clinical and biological variables and the response to ICIs. Secondary objectives included: safety; assessment of the relationship between clinical and biological parameters/concomitant treatments and progression-free survival at 6 months and overall survival at 6 and 12 months. Nomograms to predict these outcomes have been generated. Results: A total of 166 patients were included. An association with response was found in the presence of the high immunohistochemical PD-L1 expression, squamous cell histotype, and early line of treatment, whereas a higher probability of progression was seen in the presence of anemia, high LDH values and neutrophil/lymphocyte ratio (NLR), pleural involvement, and thrombosis before treatment. The nomogram showed that anemia, PD-L1 expression, NLR, and LDH represented the most informative predictor as regards the three parameters of interest. Conclusions: In the era of personalized medicine, the results are useful for stratifying the patients and tailoring the treatments, considering both the histological findings and the clinical features of the patients.
- 24 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 679
Open AccessClinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
Introduction: Immune checkpoint inhibitors (ICIs) have become the standard of treatment for patients with non-small cell lung cancer (NSCLC). However, there are still many uncertainties regarding the selection of the patient who could benefit more from this treatment. This study aims to evaluate the prognostic and predictive role of clinical and biological variables in unselected patients with advanced NSCLC candidates to receive ICIs. Methods: This is an observational and prospective study. The primary objective is the evaluation of the relationship between clinical and biological variables and the response to ICIs. Secondary objectives included: safety; assessment of the relationship between clinical and biological parameters/concomitant treatments and progression-free survival at 6 months and overall survival at 6 and 12 months. Nomograms to predict these outcomes have been generated. Results: A total of 166 patients were included. An association with response was found in the presence of the high immunohistochemical PD-L1 expression, squamous cell histotype, and early line of treatment, whereas a higher probability of progression was seen in the presence of anemia, high LDH values and neutrophil/lymphocyte ratio (NLR), pleural involvement, and thrombosis before treatment. The nomogram showed that anemia, PD-L1 expression, NLR, and LDH represented the most informative predictor as regards the three parameters of interest. Conclusions: In the era of personalized medicine, the results are useful for stratifying the patients and tailoring the treatments, considering both the histological findings and the clinical features of the patients.
- 17 April 2022
- Published by Taylor & Francis in Psychology & Health
- Vol. 39 (3) , 417-433
Perceived risk, illness perception and dispositional optimism related to COVID-19 among oncologic outpatients undergoing in-hospital treatments and healthy controls
This study aimed to explore risk estimations (perceived risk, dispositional optimism) related to COVID-19 perception and distress in oncologic outpatients undergoing active hospital treatments comp...
- 17 April 2022
- Published by Taylor & Francis in Psychology & Health
- Vol. 39 (3) , 417-433
Perceived risk, illness perception and dispositional optimism related to COVID-19 among oncologic outpatients undergoing in-hospital treatments and healthy controls
This study aimed to explore risk estimations (perceived risk, dispositional optimism) related to COVID-19 perception and distress in oncologic outpatients undergoing active hospital treatments comp...
- 13 February 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 164, 39-51
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
- 13 February 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 164, 39-51
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
- Open Access
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT) are critical to their management through the evolving COVID-19 pandemic. The AIOM-L CORONA was a multicenter, observational, ambispective, cohort study, with the intended participation of 26 centers in the Lombardy region (Italy). A total of 231 cases were included between March and September 2020. The median age was 68 years; 151 patients (62.2%) were receiving SACT, mostly chemotherapy. During a median follow-up of 138 days (range 12–218), 93 events occurred. Age ≥60 years, metastatic dissemination, dyspnea, desaturation, and interstitial pneumonia were all independent mortality predictors. Overall SACT had a neutral effect (Odds Ratio [OR] 0.83, 95%Confidence Interval [95%CI] 0.32–2.15); however, metastatic patients receiving SACT were less likely to die as compared to untreated counterparts, after adjusting for other confounding variables (OR 0.23, 95%CI 0.11–0.51, p < 0.001). Among cancer patients infected by SARS-CoV-2, those with metastases were most at risk of death, especially in the absence of SACT. During the ongoing pandemic, these vulnerable patients should avoid exposure to SARS-CoV-2, while treatment adjustments and prioritizing vaccination are being considered according to international recommendations.
Open AccessBaseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT) are critical to their management through the evolving COVID-19 pandemic. The AIOM-L CORONA was a multicenter, observational, ambispective, cohort study, with the intended participation of 26 centers in the Lombardy region (Italy). A total of 231 cases were included between March and September 2020. The median age was 68 years; 151 patients (62.2%) were receiving SACT, mostly chemotherapy. During a median follow-up of 138 days (range 12–218), 93 events occurred. Age ≥60 years, metastatic dissemination, dyspnea, desaturation, and interstitial pneumonia were all independent mortality predictors. Overall SACT had a neutral effect (Odds Ratio [OR] 0.83, 95%Confidence Interval [95%CI] 0.32–2.15); however, metastatic patients receiving SACT were less likely to die as compared to untreated counterparts, after adjusting for other confounding variables (OR 0.23, 95%CI 0.11–0.51, p < 0.001). Among cancer patients infected by SARS-CoV-2, those with metastases were most at risk of death, especially in the absence of SACT. During the ongoing pandemic, these vulnerable patients should avoid exposure to SARS-CoV-2, while treatment adjustments and prioritizing vaccination are being considered according to international recommendations.
- Open Access
- 1 January 2021
- Published by Sociedade Brasileira de Quimica (SBQ) in Revista Virtual de Química
- Vol. 13 (4) , 953-958
Flavonoids and Insecticidal Activity Against Spodoptera frugiperda of Myrsine coriacea (Primulaceae)
- 1 January 2021
- Published by Sociedade Brasileira de Quimica (SBQ) in Revista Virtual de Química
- Vol. 13 (4) , 953-958
Open AccessFlavonoids and Insecticidal Activity Against Spodoptera frugiperda of Myrsine coriacea (Primulaceae)
- Open Access
Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy)
Lombardy was the first area in Italy to have an outbreak of coronavirus disease 19 (COVID-19) at the beginning of 2020. In this context, cancer has been reported as a major risk factor for adverse outcomes and death, so oncology societies have quickly released guidelines on cancer care during the pandemic. The aim of this study was to investigate the management of cancer patients and oncological treatments during the COVID-19 pandemic and to describe the containment measures performed in our outpatient clinic at Pavia (Lombardy). A comparison with the same period of the four previous years (2019, 2018, 2017, and 2016) was also performed. Using our electronic databases, we evaluated the number and characteristics of patients accessing the hospital for anticancer drug infusion from 24 February, 2020 to 30 April, 2020 and the number of radiological exams performed. Although a significant reduction in access for therapy was seen when compared with 2019 (2590 versus 2974, access rate ratio (ARR) = 0.85, p < 0.001), no significant differences in access numbers and ARR was evident between 2020 and 2018, 2017, or 2016 (2590 versus 2626 (ARR = 0.07), 2660 (ARR = 0.99), and 2694 (ARR = 0.96), respectively, p > 0.05). In 2020, 63 patients delayed treatment: 38% for “pandemic fear”, 18% for travel restrictions, 13% for quarantine, 18% for flu syndrome other than COVID-19, and 13% for worsening of clinical conditions and death. Only 7/469 patients developed COVID-19. A significant reduction in radiological exams was found in 2020 versus all the other years considered (211 versus 360, 355, 385, 390 for the years 2020, 2019, 2018, 2017, and 2016, respectively, p < 0.001). The low incidence of COVID-19 among our cancer patients, along with the hospital policy to control infection, enabled safe cancer treatment and a continuum of care in most patients, while a small fraction of patients experienced a therapeutic delay due to patient-related reasons.
Open AccessImpact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy)
Lombardy was the first area in Italy to have an outbreak of coronavirus disease 19 (COVID-19) at the beginning of 2020. In this context, cancer has been reported as a major risk factor for adverse outcomes and death, so oncology societies have quickly released guidelines on cancer care during the pandemic. The aim of this study was to investigate the management of cancer patients and oncological treatments during the COVID-19 pandemic and to describe the containment measures performed in our outpatient clinic at Pavia (Lombardy). A comparison with the same period of the four previous years (2019, 2018, 2017, and 2016) was also performed. Using our electronic databases, we evaluated the number and characteristics of patients accessing the hospital for anticancer drug infusion from 24 February, 2020 to 30 April, 2020 and the number of radiological exams performed. Although a significant reduction in access for therapy was seen when compared with 2019 (2590 versus 2974, access rate ratio (ARR) = 0.85, p < 0.001), no significant differences in access numbers and ARR was evident between 2020 and 2018, 2017, or 2016 (2590 versus 2626 (ARR = 0.07), 2660 (ARR = 0.99), and 2694 (ARR = 0.96), respectively, p > 0.05). In 2020, 63 patients delayed treatment: 38% for “pandemic fear”, 18% for travel restrictions, 13% for quarantine, 18% for flu syndrome other than COVID-19, and 13% for worsening of clinical conditions and death. Only 7/469 patients developed COVID-19. A significant reduction in radiological exams was found in 2020 versus all the other years considered (211 versus 360, 355, 385, 390 for the years 2020, 2019, 2018, 2017, and 2016, respectively, p < 0.001). The low incidence of COVID-19 among our cancer patients, along with the hospital policy to control infection, enabled safe cancer treatment and a continuum of care in most patients, while a small fraction of patients experienced a therapeutic delay due to patient-related reasons.